GlobeNewswire

YouVersion Bible App announces most popular Bible verse of 2018

Del

Most downloaded Bible app continues to gain momentum

OKLAHOMA CITY, Dec. 04, 2018 (GLOBE NEWSWIRE) -- The YouVersion Bible App, which has been installed on more than 350 million devices worldwide, continued to see Bible engagement increase throughout its 10-year anniversary this year. Today, YouVersion announces the most popular Bible verse of 2018.

The most shared, bookmarked, and highlighted verse by YouVersion community members around the world this year is Isaiah 41:10: “Don’t be afraid, for I am with you. Don’t be discouraged, for I am your God. I will strengthen you and help you. I will hold you up with my victorious right hand.”

“This year’s data shows people worldwide are continuing to turn to the Bible in search of comfort, encouragement, and hope,” said Bobby Gruenewald, Pastor, Innovation Leader for Life.Church and YouVersion Founder. “We’re humbled that 10 years after its release, people continue to use the YouVersion Bible App in record numbers to connect with God’s Word.”

With more than 1,800 versions in more than 1,250 languages, Bible reading in the app is on the rise across several continents. With the addition of a new Japanese Bible version within the app, Bible engagement in Japan saw year-over-year growth of 104 percent. Additionally, Bible engagement in Eastern Europe is growing quickly with Romania seeing an increase of 100 percent. In South America, Chile and Argentina are the fastest growing countries with 79 percent and 60 percent growth in Bible engagement, respectively.

“Many of us grew up with the ability to read the Bible in our heart language, but countless people around the world don’t have that privilege. That’s why we’re passionate about making the Bible available in more languages through the app,” said Gruenewald. “We’re eternally grateful to the generous publishers and Bible societies who have joined us in the mission of increasing worldwide access and engagement with the Bible.”

Bible engagement reached new heights this year as YouVersion data showed a 27 percent increase in daily active users compared to last year. In fact, the YouVersion community listened to 4.2 billion chapters and read more than 27.2 billion chapters of the Bible this year, which is a year-over-year increase of 40 percent and 62 percent.

Additionally, the YouVersion community has been taking advantage of habit formation features like Bible Plans, which help users develop the discipline of daily Scripture reading. This year, users completed more than 950 million Bible Plan days, a 59 percent increase compared to 2017. Contributing to this increase is the addition of more than 1,800 Bible plans this year, 34 percent of which are in non-English languages.

Throughout 2018, the YouVersion community also took advantage of social sharing features to share a record-breaking 409 million Bible verses, including text and Verse Images. To further this momentum, YouVersion launched Bible Lens in August as a new way to help people see how the Bible intersects with their daily lives. Bible Lens is a free app that matches relevant Bible verses with a person’s photos and automatically creates visually appealing, sharable artwork. Within the first weekend, app users drove Bible Lens to the top of Apple's App Store charts as it reached #2 of all apps and #1 in the Lifestyle category.

YouVersion also saw significant growth in its Bible App for Kids, which released in 2013. With 9 languages added this year, children can now experience the animated Bible stories and interactive games in 42 different languages. Compared to last year, the number of app installs has increased by 55 percent, totaling nearly 27 million devices worldwide.

“This generation is on pace to become the most Bible-engaged generation ever, and we believe the Church should keep investing in new technologies to help adults and children connect with the Bible,” said Gruenewald. “We’re honored to be a part of how God is reaching people around the globe through His Word, and we’re eager to see how Bible-engaged people make a difference in this world for decades to come.”

For more information about the YouVersion community’s Bible engagement in 2018, visit share.bible.com/2018.

About YouVersion            
Created by Life.Church, YouVersion is on a mission to help people engage with the Bible. The team designs and builds experiences that make it easy for people to integrate the Bible into their everyday lives. Since 2008, the Bible App has offered a free Bible experience that can be accessed on smartphones, browsers, voice platforms, and more. The Bible App for Kids launched in 2013 and engages children with Bible stories on an age-appropriate level. The newest app, Bible Lens, analyzes objects in photos, finds the most relevant Bible verse to match, and automatically creates beautiful, shareable artwork. For more information about YouVersion, visit youversion.com.

MEDIA CONTACTS:
Rachel Feuerborn
405-216-7072
rachel.feuerborn@life.church

Photos accompanying this announcement are available at: 

http://www.globenewswire.com/NewsRoom/AttachmentNg/36eb6a4c-cc72-41ec-bdc3-bc4ab49dd1df

http://www.globenewswire.com/NewsRoom/AttachmentNg/350e9089-4a1b-455a-ab07-7dcd399b9357

http://www.globenewswire.com/NewsRoom/AttachmentNg/85736d34-290b-4088-818c-96ef061e6e29

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Gainsight Unveils the Customer Cloud, the Future of Customer Success Technology23.5.2019 19:30:00 CESTPressemelding

New Products Announced at Pulse 2019 to Drive Customer Success Across the Enterprise SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- Today, Gainsight® launched the Customer Cloud —a first-of-its-kind solution for subscription businesses looking to adopt a customer-centric philosophy that enables them to retain customers while also driving company growth post-sale. According to the 2018 Subscription Economy Index report, subscription companies are growing five times faster than S&P and retail sales. The Gainsight Customer Cloud caters to these businesses by combining the company’s Customer Success and Product Experience products with three new product innovations to offer a powerful set of solutions for businesses to optimize their subscription strategies through technology. “With the maturity of cloud technology and the subscription economy, customer expectations have drastically changed. Companies are struggling to leverage existing tools to satisfy the increasing demands of their cus

Lowered Return Expectations Among Several Trends Pointing to a Shift in Private Markets Due Diligence says New eVestment Survey23.5.2019 15:30:00 CESTPressemelding

ATLANTA, May 23, 2019 (GLOBE NEWSWIRE) -- Private markets funds have continued to rake in new commitments from institutional investors eager to diversify their portfolios and capture the returns private markets investments can offer. However, investors are now tempering their private markets return expectations. Coupled with other industry trends, this will have implications for private markets fundraising and due diligence according to a new eVestment report, produced in association with parent company Nasdaq. The 2019 eVestment Private Markets Due Diligence Survey of institutional investors, consultants and private markets fund managers finds that 52% of investors expect returns in the space to decline in the future (page 16). Only 12% of investors expected private equity returns to increase, with the balance – 36% – expecting returns to stay about the same. Forty-seven percent of investors surveyed expect to see lower returns in venture capital vs. just 16% of investors who expect r

Collibra Announces 2019 Excellence Awards Winners23.5.2019 15:00:00 CESTPressemelding

American Express, Deloitte, and Lloyds Banking Group recognized as leaders in harnessing data to drive digital transformation NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Collibra, the leader in enterprise data governance and catalog software, today announced the winners of the 2019 Collibra Excellence Awards. Presented at the annual Data Citizens conference in New York, the awards honor teams and individuals driving innovative data strategy by collaborating with Collibra. “In today’s market, organizations that are able to maximize data have the power to transform entire industries,” said Felix Van de Maele, co-founder and CEO of Collibra. “We’re proud to honor the recipients of the Collibra Excellence Awards, a cutting-edge group at the forefront of data-driven innovation.” The 2019 Collibra Excellence Award Winners: American Express — Distinguished Data Program of the Year American Express was recognized for its data governance transformation, which began as a compliance initiative and

XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa23.5.2019 14:20:00 CESTPressemelding

AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The study will further evaluate efficacy of bermekimab in HS and guide dosing strategies for the anticipated Phase 3 registration study. The Company expects the first patient to be enrolled during the third quarter of 2019. The Phase 2b study follows two previous successful clinical studies of bermekimab to treat HS. XBiotech recently evaluated bermekimab in a phase 2 study involving two groups of patients with HS: those who had no prior treatment with biologics; and those who had failed the only approved biological therapy to treat HS. The study, whi

LGC CAPITAL Announces Results of Annual Meeting, Appointment of New Chairman and Approval of Name Change to Elixxer Ltd.23.5.2019 14:00:00 CESTPressemelding

MONTRÉAL, May 23, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held yesterday in Montreal, Quebec. At the Meeting, all five of the nominees listed in the Corporation’s management information circular dated April 17, 2019 were elected as directors, all with a vote of more than 92% of the shares voted in their favour. Accordingly, the directors of LGC for the ensuing year are Mohammed Ghafari, Mazen Haddad, Rafi Hazan, David Lenigas and Ferras Zalt. At the Meeting, shareholders adopted a special resolution approving a change in the name of the Corporation to “Elixxer Ltd.” or such other name as the Corporation’s directors may determine. The special resolution was supported by 98.94% of the votes cast at the Meeting. The Corporation intends to proceed with the name change as expeditiously as possible. Shareholders also adopted: a special

Merus Announces 2019 Annual General Meeting of Shareholders23.5.2019 14:00:00 CESTPressemelding

UTRECHT, The Netherlands, May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General Meeting of Shareholders will be held on June 12, 2019 at 1:00 pm (CEST) at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus’ website (www.merus.nl) under “Financial Information”. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clin